

SOHM INC.

ANNUAL REPORT

FOR THE YEAR ENDED

December 31, 2013

**ISSUER INFORMATION FILE PURSUANT TO SECURITIES AND EXCHANGE
COMMISSION RULE 15c2-11**

**SOHM, Inc.
6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA
Telephone: (714) 522-6700
Fax: 714-523-4329
www.sohm.com**

December 31, 2013

(A Nevada Corporation)

TRADING SYMBOL: SHMN

CUSIP #: 83408P 108

TAX EIN NUMBER: 20-3161788

SHAREHOLDERS OF RECORD: 1760

Information provided pursuant to Rule 15c2-11 of the Securities and Exchange Act of 1934, as amended.

The information furnished herein has been prepared from the books and records of the issuer by its officers and directors in accordance with the Securities and Exchange Commission Rule 15c2-11 as amended, and is intended only as a securities dealer informational file and: No dealer, salesman or any other person has been authorized to give any information, or to make any representations, not contained herein in connection with the issuer. Such information or representations, if made, must not be relied upon as having been authorized by the issuer, and: Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written above.

Information required to conform with the provisions of subparagraph (a) (4) of Rule 15c2-11 promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934.

PART A General Company Information

Item I **SOHM, Inc. (the “Issuer” or the “Company”) formerly Alpine TLI Group, Inc.**

Item II **6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA
Telephone: (714) 522-6700
Facsimile: (714) 523-4329
Web site: www.sohm.com**

Investor relations's person's name: N/A
Investor relation person tele #: 714-522-6700
Investor relation persons email: IR@SOHM.COM
Investor relation person address: SOHM Inc.
6920, KNOTT AVE # A-C
BUENA PARK, CA 90621

Investor relation person mailing address: As Above

Item III The Issuer was organized under the corporate laws of the State of Nevada on July 6, 2005. The Issuer operated as a California C Corporation from January, 1998, until it merged with Alpine TLI Group in August, 2008 and changed name to SOHM Inc.

Part B Share Structure

Item IV **COMMON STOCK and SERIES A PREFERRED STOCK**
TRADING SYMBOL: SHMN
CUSIP #: 83408P 108

Item V Par or Stated Value and description of the Security

- A. \$0.001 par value for both Common and Preferred Stock
- B. Common & Preferred Stock A

- 1.The Common no dividend rights. Each share of common stock is entitled to One (1) vote on matters brought to vote by the shareholders.
- 2.The Preferred stock has no dividend rights. The preferred stock has voting rights equal in all aspects to the number of Common Stock represented by such Preferred Stock on an as converted basis and shall be entitled to vote on any and all matters brought to a vote of shareholders of Common Stock and all matters brought to a vote of shareholders of Preferred Stock. Each share of preferred stock shall be convertible into one percent (1%) of the then issued and outstanding shares of common stock of the Company. The preferred stock has liquidation rights equal to the par value of each share of preferred stock.
- 3.There are no other material rights of common stockholders
- 4.There is no reason that would delay, defer, or prevent a change in control of the issuerer per the issuer's Articles of Incorporation or the issuer's by-laws.

Item VI **Common Stock**

i) As of 12/31/13:	
ii) Authorized shares of Common Stock:	1,000,000,000
iii) Shares outstanding:	496,063,404
iv) Shares in the public float:	89,474,492
v) Total number beneficial number of shareholders:	1760
vi) Total number of shareholders of record:	1760

i) As of 12/31/13:	
ii) Authorized shares of Preferred Stock:	100
iii) Shares outstanding:	51
iv) Shares in the public float:	0
v) Total number beneficial number of shareholders:	1
vi) Total number of shareholders of record	1

B

i) As of the fiscal year (12/31/12):	
ii) Number of shares authorized:	1,000,000,000
iii) Number of shares outstanding:	469,063,353
iv) Freely tradable shares (public float):	76,439,441
v) Total number of beneficial shareholders:	1760
vi) Total number of shareholders of record:	1760

i) As of the fiscal year (12/31/11):	
ii) Number of shares authorized:	1,000,000,000
iii) Number of shares outstanding:	432,278,806
iv) Freely tradable shares (public float):	50,065,231
v) Total number of beneficial shareholders:	2084
vi) Total number of shareholders of record:	2084

Item VII: Stock Transfer Agent"

Holladay Stock Transfer, Inc.

2939 North 67th Place
 Scottsdale, Arizona 85251
 Telephone: 480-481-3940

Holladay Stock Transfer, Inc. is registered with the Securities and Exchange Commission, which is the appropriate regulatory authority of the transfer agent.

PART C Business Information

Item VIII The Nature of the Issuer's Business

A Generic Pharmaceutical Manufacturer

Company Overview

SOHM, Inc. (SHMN) is a pharmaceutical manufacturer that produces and markets generic drugs for all major treatment categories. In February, 2009, the Company obtained a direct manufacturing license under Current Good Manufacturing Practice (CGMP) and initiated processes to be compliant with World Health Organization (WHO) regulations to produce generic as well as OTC pharmaceuticals. This authorization process provides the Company with manufacturing competencies for a wide variety of products covering various therapeutic segments. SOHM has private label license agreements with two companies to produce pharmaceuticals and OTC products.

The Company's manufacturing facility, located in India, enables low production costs without compromising quality. SOHM develops, manufactures and markets generic pharmaceuticals in various dosage forms, including tablets and capsules, creams and topicals, ointments, liquids and injectables. At present, SHMN has global licenses to manufacture 30 products and approximately 300 generic drugs and product formulations for distribution.

SOHM markets and sells its generic drugs globally but focuses primarily on emerging markets in Africa, Latin America, Southeast Asia and the European Union. The Company's global headquarters is located in North America and it has offices in China, India and the U.K.

Generic Drug Manufacturing Expertise

SOHM's proprietary processes and formulation capability allow it to develop generic formulations of brand name drugs that don't infringe on valid patents relating to the brand-name product. Demand for generic pharmaceuticals is increasing as a result of increasing awareness and acceptance of generics by consumers, physicians and pharmacists globally. In addition, government agencies and private managed care/ insurance programs encourage the substitution of generics for brand-name pharmaceuticals as a cost savings measure. Sohm has developed ability to bridge the gap between demand and supply for generic and OTC products cost effectively with consistent quality deliverables.

Infrastructure To Support Manufacturing and Export

By consolidating its pharmaceutical assets in India, the Company has a generic drug manufacturing hub where it capitalizes on low prices, strong marketing and global recognition of India's emerging role as a leading drug manufacturing center. In October 2008, SOHM obtained pharmaceutical drug licenses that enable it to sell in Africa, Latin America and Southeast Asia. In February 2009, SHMN obtained a direct manufacturing license for generic pharmaceuticals. This license completes the needed infrastructure development for its India manufacturing hub.

1. Issuer is a Nevada Corporation;
2. The Issuer operated as a California C Corporation from January, 1998, until it merged with Alpine TLI Group in August, 2008. The Issuer's predecessor was organized under the corporate laws of the State of Nevada on July 6, 2005.
3. The Issuer's fiscal year end date is December 31.
4. The issuer and/or any predecessor has not, and is not, in the process of filing bankruptcy, receivership or any similar proceeding.
5. On August 25, 2008, SOHM, Inc., entered into an agreement with Alpine TLI Group, Inc., the predecessor. The agreement was to acquire SOHM, Inc. and pass control of the Company to the then current officers of SOHM, Inc. Swati Shah, President and CEO and Sharad Joshi, Secretary/Treasurer and CFO.

6. No default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the Issuer to make payments as of the most recent quarter and year end.
7. The Issuer changed control when it merged in September 2008.
8. The increases in outstanding equity securities have increased by more than 10%.
9. Below is a description of any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization

On August 26, 2008, the Board of Directors and majority shareholders of Alpine TLI Group, Inc. voted and confirmed the following:

- **Corporate Name Change, CUSIP Number Change and New Business Direction**
The stockholders and Board Members of Alpine TLI, Group voted to confirm the change of the name of the corporation to SOHM, Inc and also to apply for a new CUSIP number. The name change and CUSIP number change reflects the companies new business direction to directly supply dyes, chemicals, pigments, and supply steel wires to manufacturers for springs, automobiles and garment/textile industries through private label agreements.
 - **Merger with SOHM Inc.**
The stockholders and Board Members voted to confirm the merger with SOHM, Inc.
 - **Reverse Split**
The stockholders and Board Members voted to confirm a 50:1 reverse split.
 - **CEO and Chairman Change**
The stockholders and board members voted to confirm a CEO and Chairman change effective September 5, 2008. Then current CEO and Chairman resigned and Swati Shah assumed the position of President, CEO and Chairman of the Board and Sharad Joshi assumed the position of Secretary/Treasurer, CFO and Board Member. Mr. Sharad Joshi resigned as CFO effective March 31, 2009. Earlier this year the stockholders & Board members voted to confirm a CEO & Chairman change effective January 15, 2011. The then current CEO & Chairman Swati Shah resigned as President & CEO and took over as Vice President Secretary & Board Member. Mr. Shailesh Shah assumed the position of President, CEO & Chairman of the board.
10. Issuer's securities have not been de-listed and are not in the process of being de-listed by the Securities and Exchange Commission or the NASD.
 11. There are no current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations.

(B) Business of Issuer.

1. The Primary SIC Code for the Issuer is 2834.
2. The Issuer is currently conducting operations
3. The issuer is not and has not been a shell company

4. There is no parent, or affiliate of the issuer
5. The effect of the existing and probable new government regulations is that issuer is alert and watchful so as to be able to re-evaluate portions of its business plan
6. No amount has been spent during each of the last two fiscal years on research and development activities, therefore no cost of such activities are borne directly by customers
7. There are no known costs or effects of compliance with environmental laws, neither International, federal, state or local.
8. The Company currently has one hundred forty five, (145) are full time employees.

(C) Investment Policies

1. Investments in real estate or interest in real estate

The Issuer does not intend to invest in Real Estate outside of ownership in its executive offices or manufacturing facilities

2. Investments in real estate mortgages

The Issuer does not intend to invest in any type of real estate mortgages.

3. Investments in Securities

The Issuer does not intend to invest in short term or long term securities

Item IX The nature of products and services offered

A *Services Provided by SOHM, Inc., and their Markets*

SOHM develops and commercializes generic pharmaceuticals, utilizing its controlled-release and other in-house and formulation technologies. The Company focuses on developing generic versions of brand-name products for which the patents are near expiration or expired and requiring a proprietary formulation expertise. By innovating processes, and applied innovation, the Company's proprietary processes and formulation skills allow it to develop generic versions that replicate the brand-name products' physiological effects but don't infringe on any valid patents.

B The Company actively reviews pharmaceutical patents and seeks opportunities to challenge patents it believes are either invalid or would not be infringed by a generic version. SOHM also enters into collaboration, alliances and partnerships to acquire rights to pharmaceuticals it does not own and to share development costs or resolve patent barriers to entry. Overall, the Company's generic product development strategy leverages a legal strategy predicated on non-infringement of established brand name pharmaceuticals and speed of filing and also provide applied innovation.

C The Company has a direct manufacturing license of generic pharmaceuticals and currently produces and markets 300 plus generic pharmaceutical products along with dermatology and Nutraceutical products. The classification and industry position allows for a significant increase in profit margins and scalability of manufacturing operations. This license provides SOHM the

production infrastructure to operate as a corporate manufacturing hub located in India for the production and export of generic pharmaceuticals.

CORPORATE OVERVIEW

The Company's manufacturing facility is located in Ahmedabad City, India, in an area considered one of the safest in India and perfect for pharmaceutical operations. The facility is approximately 10,500 sq ft and the entire land area is approximately 15,000 sq ft. There is additional space available for future capacity expansions and growth and storage requirements. In February 2009, SOHM's manufacturing facility was licensed by the India FDA. The license indicates compliance with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and compliant with World Health Organization (WHO) regulations.

The manufacturing facility provides complete technical support for production activities and houses the following:

- A quality control laboratory with instruments to provide, chemical and microbiological analytical support; to provide constant in process checks
- A spacious raw materials storage area which provides separate storage facilities for incoming materials, quarantine materials, released materials and a separate section for sampling under controlled environment and isolated areas for dispensing of raw materials; through documented SOPs for stringent control systems of checks and balances.
- A finished goods warehouse for storage and distribution of finished goods.

Corporate Strategy

The Company produces premium-quality, affordable pharmaceuticals and meets the changing needs of the drug market with a continual flow of new products, broadening its product portfolio, optimizing a global supply chain, helping customers more efficiently manage their inventory and customizing distribution and shipping based on specific customer needs. SOHM plans to grow by extending its leadership position in emerging generic pharmaceutical markets in Africa, Latin America, Southeast Asia and other important international markets.

Key aspects of the Company's strategy include:

- Undertake applied innovation to find optimum fit between demand and supply gaps in generic industry.
- Increasing generic R&D capabilities, and applied formulations with continuous incremental improvement which adds up to sustained innovative output, and greater production capacity;
- Establishing a high level of operational effectiveness oversight and quality control systems;
- Bridge the gap between demand and supply in cost effective generics and branded generics; Providing high-quality products in markets that are currently under served, poorly served, or under-subscribed by existing suppliers;
- Using cost-effective, up-to-date instruments and equipment and machineries; on an ongoing basis.
- Employing advanced electronic and information technology to reduce staffing and other operational costs; providing more system based output with minimal human errors,
- Continuing to business scanning actively seek and evaluate potential mergers, acquisitions, collaborations and other business combinations; to enlarge capacities, competencies and innovations;
- Side stepping head-to-head competition with an established business in regions that already are well served and develop alternatives for unmet needs to enlarge innovative generics portfolio.

Sales and Marketing

The Company's focus on cluster of segment of customers who are drug wholesalers, mass merchandisers, warehousing chain drug stores, and mail-order pharmacies who have extensive chain of retailers and loyal customer base.. by doing so, Sohm does not need to re-invent its grass root customers but rather SOHM markets its products both directly and through partner alliance agreements. SOHM focuses on fast growing, underserved emerging markets in the Far East, Africa, newly added European Union states and Latin America. Despite the challenges of the current economic climate, much of the world's population has a great need for basic pharmaceuticals, but these drugs are either too expensive or not available to vast populations in these regions. The Company recently expanded its generic drug distribution to address emerging pharmaceutical markets in Indonesia, Thailand, the Philippines, and Malaysia.

The Company's marketing effort focuses on:

- Identifying, through careful market research, un-served or underserved niche markets;
- Combining the core pharmaceutical business with ancillary marketing concepts, activities and operations;
- Identifying, negotiating, and entering into partnerships with larger, more established distributors;
- Utilizing advanced electronic and informational technologies in sales and marketing;
- Accommodating special and ethical products when and where sufficient demand exists.

Products

SOHM produces and markets generic drugs covering all major treatment categories. Its product list includes anti-arthritic/analgesics, anticancer drugs, antifungals, anti-infectives, cardiovascular agents, central nervous system, dermatological, gastrointestinal and respiratory drugs, biotechnology products, hormones, anesthetics, antidiabetics, antiemetics, dermatologicals, immunosuppressive agents, ophthalmic drugs, and treatments for benign prostatic hyperplasia

SOHM's manufacturing facility is licensed by the India FDA to manufacture:

- **TABLETS:** uncoated; coated; chewable; dispersible;
- **CAPSULES** - hard gelatin capsules; dry syrup;
- **ORAL LIQUIDS** - syrups and suspensions;
- **OINTMENT** - external creams & gels;
- **β - LACTUM:** tablets; capsules; dry syrup;
- **INJECTABLES.**

E Sources of raw materials for the Company's generic drugs are freely available.

F The non-dependence on one or a few major customers is a strength.

G The Company maintains trademarks for all of its private label products.

H In February 2009, SOHM's manufacturing facility was licensed by the India FDA. The license indicates compliance with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and World Health Organization (WHO) regulations.

Item X The Nature and Extent of the issuer's facilities.

The Issuer occupies approximately 1500 square feet of leased office space at the rate of \$2,200.00 per month. The Issuer believes that the space is in good condition and properly insured. The major assets of the company comprise the following:

The Company is Headquartered in Buena Park, California, U.S.A. with Sales Office at Corona California and the Company's manufacturing facility is located in Ahmedabad City, India, in an area

considered one of the safest in India and perfect for pharmaceutical operations. The facility is approximately 10,500 sq ft and the entire land area is approximately 15,000 sq ft.

Property of the issuer is in good condition. There are no limitations on the expansion capability of the Company.

Part D **Management Structure and Financial Information**

Item XI **The name of the chief executive officer, members of the board of directors, as well as control persons.**

A. **Officers and Directors**

1.

i) Executive Officers

- | | |
|--------------------------|----------------------------|
| 1) Shailesh Shah | President and CEO |
| 2) Swati Shah Secretary, | Treasurer & Vice President |

ii) Directors

- | | |
|------------------|-----------------------|
| 1) Shailesh Shah | Chairman of the Board |
| 2) Swati Shah | Director |

iii) Others

- 1) There is no General Partner
- 2) Control persons are President and Vice President

2.

i) **Shailesh Shah - President & CEO**

6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA

ii) **Swati Shah – Secretary Treasurer and Vice President**

6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA

i) **Swati Shah – Vice President & Treasurer**

6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA

Education – Bachelor of Commerce/Bachelor of Law from Gujarat University

Employment History –

SOHM, Inc. – Buena Park, CA

Secretary Treasurer and Vice President

2011-Present

President & Chief Executive Officer

2008 - 2011

SOHM, Inc., is a leading US-based Import-Export Organization specializing in global trading of a diversified product portfolio ranging from Manufacturing, Medical Equipment, Pharmaceuticals and Chemicals.

The Company has established and maintains long standing relationships in China and India, the world's largest product suppliers. Our Asia-Pacific manufacturers allow us to import, export, and/or source quality products in China and India; sharply reducing business costs and increasing the profits of our client corporations.

SOHM Hospitality, LLC, Buena Park, CA

2004-2008

President

SOHM Hospitality offers years of motel operating experience in the hospitality industry. Our expertise, service standards, and profitable performance have made us a leader in motel management. We offer sound leadership in operations, finance and marketing based on tried and tested operating performance standards.

A relationship with SOHM Hospitality Group starts with listening to your goals and developing a sound business plan to meet desired objectives. Our management style is hands-on, defined and supported by processes, written procedures and policies that have proven to enhance property revenues and performance.

Cherokee International, LLC, Tustin, CA

1996-2006

Supervisor in Quality Control Dept

Cherokee International Corporation engages in the design and manufacture of power supplies for original equipment manufacturers (OEM) worldwide. It offers mid- to high-end custom and modified standard commercial power supplies, such as DC/DC products. The companies OEM customers include servers and storage, networking, wireless infrastructure, medical, high-end mainframes, industrial process controls, and other electronic equipment industries. Cherokee International Corporation was founded in 1978 and is headquartered in Tustin, California.

(ii) Shailesh Shah – President & CEO

6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA

Shailesh Shah is **President & CEO** of SOHM, Inc. Shailesh has over twenty four years experience in IT consulting, human resource management, and international trade. Shailesh has had multiple successes in leading and managing new business initiatives which integrate people, process, and technology. Successfully assisted prospective importers and exporters with evaluating import-export potential, identifying target markets, developing market entry strategies, building distribution networks and the "mechanics" of international trade. Mr. Shah Built an extensive network of contacts with foreign and domestic companies/organizations that can help clients find customers and set up channels of distribution overseas. Set up affiliations with professionals in international transportation, law, insurance and finance to provide specialized assistance to clients. Shailesh has extensive experience in research and development of potential markets for several lines of industrial and consumer products. Shailesh has a Bachelor of Science and graduate degrees in International Business, Marketing, and Sales, Post graduate Diploma in International Business Management Post Graduate Diploma in Marketing and Sales Management

Mr Shah has worked effectively with regional development centers, state and federal agencies, legislators, U.S. and foreign trade offices, chambers of commerce, and other international economic development organizations to promote exporting through jointly sponsored programs. Developed and implemented a consulting program for the company's new International Trade Division to provide one-on-one consulting services to prospective clients in India, the UK and Africa. He developed resources to meet the demands of clients and consulted clients on introducing their products into foreign markets. He gained extensive experience in international market research, formulation of marketing programs, international distribution, quality control, international credit and shipping procedures and all other activities necessary to effectively service a critical manufacturer in India and Africa.

PROFESSIONAL MEMBERSHIP

► CERTIFIED MANAGEMENT CONSULTANTS (CMC), IMC, WASHINGTON, DC

- ▶ SENIOR MEMBER, AATCC, NC
- ▶ ROTARY CLUB OF BUENA PARK, CA
- ▶ LIFE MEMBER OF AHMEDABAD MANAGEMENT ASSOCIATION, INDIA
- ▶ MEMBER OF ALL INDIA MANAGEMENT ASSOCIATION, NEW DELHI, INDIA
- ▶ BUENA PARK CHAMBER OF COMMERCE
- ▶ CALIFORNIA CHAMBER OF COMMERCE, SACRAMENTO, USA
- ▶ US CHAMBER OF COMMERCE, WASHINGTON DC, USA

4. There are no outside board memberships and no other affiliations

5. Compensation to the Officers

i) **Shailesh Shah - President & CEO**

Is compensated from the issuer:

ii) **Swati Shah – Secretary, Treasure and Vice President**

Is compensated from the issuer:

6. Number of Shares Owned Beneficially - Common Stock A

iii) **Shailesh Shah - President & CEO**

107,604,173 Shares

iv) **Swati Shah – Secretary, Treasure and Vice President**

96,180,086 Shares

B. None of the above Officers or Directors has in the last 5 years been:

1. Convicted of any criminal proceedings either named or as a defendant.

2. Has not had an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or banking activities

3. Has not had a finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated.

4. Has not had an entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Disclosure of family relationships.- Shailesh Shah and Swati Shah is husband and Wife.

D. Disclosure of Related party Transactions in not applicable because there were no transaction that occurred in the last three years for an amount greater than \$120,000 nor an amount greater than one percent of the average of the issuer's total assets at year over this same three year period.

E. Disclosure of Conflicts of Interest: There are no Conflicts of Interest

Item XII Financial Information for the Issuer at 12-31-2013 is incorporated into this disclosure.

The financial statements are posted through the OTC Disclosure and News Service

See OTC Disclosure Service at pinksheets.com

The following is presented for cross reference to the financial information

Item XIII Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence

See OTC Disclosure Service at pinksheets.com

Item XIV Beneficial Owners:

- Swati Shah – 96,180,086 Shares – 19.38%

All of the 96,180,086 shares of common stock which are currently held, directly or indirectly, by the above beneficial owners have been issued in reliance upon Rule 144 under the Securities Act of 1933. In general, under Rule 144 a person, or persons whose shares are aggregated, who has beneficially owned shares acquired in a non-public transaction for at least one year, including persons who may be deemed affiliates of the company, as defined, would be entitled to sell within any three-month period a number of shares that does not exceed the greater of 1% of the then outstanding shares of common stock, or the average weekly reported trading volume during the four calendar weeks preceding such sale, provided that current public information is then available. If a substantial number of the shares owned by these shareholders were sold under Rule 144 or a registered offering, the market price of our common stock could substantially decline.

- Shailesh Shah – 107,604,173 shares – 21.69%

All of the 107,604,173 shares of common stock which are currently held, directly or indirectly, by the above beneficial owners have been issued in reliance upon Rule 144 under the Securities Act of 1933. In general, under Rule 144 a person, or persons whose shares are aggregated, who has beneficially owned shares acquired in a non-public transaction for at least one year, including persons who may be deemed affiliates of the company, as defined, would be entitled to sell within any three-month period a number of shares that does not exceed the greater of 1% of the then outstanding shares of common stock, or the average weekly reported trading volume during the four calendar weeks preceding such sale, provided that current public information is then available. If a substantial number of the shares owned by these shareholders were sold under Rule 144 or a registered offering, the market price of our common stock could substantially decline.

Item XV The name, address, telephone numbers, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and discourse.


- | | |
|----------------------------------|--|
| 1- Investment Banker | None |
| 2- Promoters | None |
| 3- <u>SEC Counsel</u> : | Chase Chandler
Brunson, Chandler & Jones, PLLC
175 S. Main Street, 15th Floor
Salt Lake City, UT 84111 |
| 4- Accountant or Auditor | Hartley Moore Accountancy Corporation
11801 Pierce Street, Suite 256
Riverside, CA 92505
Phone: (714)627-2506 |
| 5- Public Relations Consultant | N/A |
| 6- Investor Relations Consultant | NA |

Item XVI Management’s Discussion and Analysis or Plan Operation

Mission and Organizational Structure:

Sohm, Inc. (SHMN) is a generic drug manufacturer that produces and markets generic drugs for all major treatment categories globally. The core idea is to provide generics drugs cost effectively in order to bridge the gap between demand and supply . The Company not only works on applied innovation for branded generics but also provides support to while label manufacturing to build reach to ailing millions. The Company focuses on developing generic versions of brand-name products for which the patents are near expiration or expired. The Company competes on the basis of its low cost structure, aggressive growth, marketing strategy and focusing on underserved markets.

Organization Structure



Performance goals, Objectives and Results:

Non-Infringement and Early Introduction

Sohm actively reviews pharmaceutical patents and seeks opportunities to introduce its generic products where the patents have expired or are invalid. The Company intends to pursue its aggressive growth strategy through strategic alliances. These partnerships will help the Company acquire rights to pharmaceuticals, resolve patent barriers to entry while sharing development costs. The business strategy puts emphasis on non-infringement of established brand name pharmaceuticals coupled with speed of filing. The enlarged capacities through mergers , acquisitions and collaborations also bring about enlarged competencies and soft skills beyond machines and systems,

Low Cost Manufacturing Facility

The Company's manufacturing facility is located in Ahmedabad, India. The total available area is approximately 15,000 sq ft. and the current facility occupies approximately 10,500 sq ft. There is additional space available for future growth. The manufacturing facility is compliant with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and World Health Organization (WHO) regulations. The manufacturing facility is fully equipped and provides complete technical support for production activities. The location provides the Company with a low cost advantage, including lower development costs, low fixed asset costs, low clinical trial costs and low cost of workers. The location also is surrounded by ecology of institutes from where steady supply of capable and trained professionals are easily available building competencies beyond machines and systems.

Focus on Underserved Markets

The Company intends to identify un-served or underserved niche markets to introduce its products. SHMN markets its products both directly and through partner alliance agreements. SHMN focuses on fast growing, underserved emerging markets in the Far East, South East Asia Africa, newly added European Union states, CIS Countries, and Latin America. These regions lack basic pharmaceuticals and branded drugs are either very expensive or unavailable largely. The Company recently expanded its generic drug distribution to address emerging pharmaceutical markets in Indonesia, Thailand, the Philippines and Malaysia. The Company expects to expand its range of generic pharmaceuticals through intensive research and development as well applied innovations in both generics, cosmeceuticals, and Nutraceuticals. The generic drug development strategy of the Company is represented below.

Financial Statements for the year 2011 as well as 2012 are explained in this report.

Going Concerns

The current economic environment may pose a challenge for the Company in raising funds for business. The economic recovery in the developed world remains sluggish with doubts about sustainability of recovery. The Company must continually have access to the capital markets to raise funds for operations. Lack of working capital adequacy financing may hinder further growth and slow the implementation of the business plan. The increased stringency of regulatory controls, demand for increased technological advances and expansions of capacities can be vital for sustainable growth and timely availability of high value funds can accelerate the process. Building soft skill and management bandwidth is also linked with capacity reinforcements and working capital adequacies to attract, retain and deploy highly knowledge-based skill force.

The generic drugs market has significant upward growth potential. This has encouraged large and small players to tap into this opportunity. Increased competition may impact growth and margins negatively.

Pharmaceutical companies are using state and federal legislative and regulatory means to delay generic competition. If pharmaceutical companies succeed in limiting the use of generics, it would diminish SHMN's business prospects. We believe generic drugs will gain popularity as they are cost effective with the same physiological effectiveness.

System, Controls & Legal Compliance

OVERVIEW OF OPERATIONS AND ACCOUNTING POLICIES

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

The Company's operations to date have included assembling its management, marketing and sales personnel, forming strategic relationships with vendors, securing financing and launching the initial purchases of tax lien certificates.

The accompanying financial statements include financial data such as assets, liabilities, profit and loss etc. of Sohm India Pvt. Ltd. India (100% stocks of Sohm India Pvt. Ltd. Have been held by the Company and its Directors)

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying financial statements, the Company had negative cash flow from operations and incurred a net loss during the previous twenty-two months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to achieve sufficient cash flow from operations or secure adequate future financing and be therefore unable to continue as a going concern.

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments necessary for their fair presentation in conformity with U.S. generally accepted accounting principles. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results may differ from these estimates. The information included in this Form 211-75c should be read in conjunction with Management's Discussion and Analysis and financial statements and notes thereto included. Certain reclassifications have been made for consistent presentation.

Revenue Recognition

The Company generally recognizes revenue upon the accrual of interest earned on the tax lien certificates owned, as well as liquidating revenue from properties sold that the Company received through settlement of unredeemed tax lien certificates.

Deferred Revenue

The deferred revenue shown in the balance sheet is the interest earned but not collected.

Product Research and Development

Advertising, Sales & marketing

Advertising, sales & marketing costs are expensed as incurred. Advertising, sales & marketing expense totaled \$191,137.00 for the year-ended December 31, 2012 and for the year ended December 31, 2013 totaled \$ 170,003.

Inventory

Inventory is stated at the lower of cost or net realizable value. The method used for inventory is first-in first out. Inventory consists of Pharmaceutical products

Property, Equipment and Patents

Equipment is depreciated using the federal tax method over the estimated useful lives, which range from two to seven years.

Fixed assets consist of the following:

	12/31/2012	12/31/13
Fixed Assets	<u>2,034,329</u>	<u>1,913,893</u>
Total fixed assets	2,034,329	1,913,893
Less: Accumulated depreciation and Amortization	<u>(155,234)</u>	<u>(233,610)</u>
Net	1,879,086	1,680,283

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Earnings per Share

The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

The Company has no potentially dilutive securities outstanding at the end of the statement periods. Therefore, the basic and diluted earnings (loss) per share are presented on the face of the statement of operations as the same number.

Stock Based Compensation

The Company accounts for its stock based compensation based upon provisions in SFAS No. 123, Accounting for Stock-Based Compensation. In this statement stock based compensation is divided into two general categories, based upon who the stock receiver is, namely, employees/directors and non-employees/directors. The employees/directors category is further divided based upon the particular stock issuance plan, namely compensatory and non-compensatory. Each of these divisions treats the stock issuance for accounting purposes in a specific manner. The employee/directors non-compensatory securities are recorded when the stock is sold at the sales price. The compensatory stock may be recorded in one of two different methods. Compensation is calculated and recorded either at the securities' fair value or intrinsic value. The Company has selected to utilize the fair value method for valuing and recording options.

PAYABLE AND CAPITAL LEASE OBLIGATIONS:

Notes payable and capital lease obligations consist of the following:

There are long term notes payable and the long –term portion.

	For Year Ended	
	12/31/2012	12/31/13
Total Long Term Notes	910,652	1,978,978
Total Loan Payable to Bank & Others	1,904,142	1,516,483

STOCKHOLDERS' EQUITY

Authorized Capital Stock

The Company has total authorized capital of 1,000,000,100 shares consisting of 1,000,000,000 shares of common stock, \$.001 par value per share and 100 Preferred Stock as of the date of the financial statements. Of the 1,000,000,000 shares authorized 496,063,404 shares were issued and outstanding as of December 31, 2013 and 432,278,806 shares were issued and outstanding on December 31, 2012 and of the 100 Preferred Shares authorized 51 shares were issued and outstanding as on December 31, 2012.

Stock Based Compensation Paid for Services of Non Employees

SFAS 123 provides that stock compensation paid to non employees be recorded with a value which is based upon the fair value of the services rendered or the stock given, whichever is more reliable. The common stock paid to non-employees was valued at the value of the stock issued. Below is a schedule which shows the common stock issued and the value of the services rendered for each of the period.

Period Ended	Shares Issued	Value
December 31, 2013	0	\$0
December 31, 2012	0	\$0
December 31, 2011	0	\$0
December 31, 2010	0	\$0
September 30, 2010	0	\$0
June 30, 2010	0	\$0
December 31, 2009	0	\$0

INCOME TAXES:

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes*. SFAS No. 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

SFAS No. 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company's opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is \$450,300 which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carry forwards, (15%). The total valuation allowance is a comparable \$450,300.

The provision for income taxes is comprised of the net change in deferred taxes less the valuation account plus the current taxes payable as shown in the chart below.

	12/31/2013	12/31/12
Net change in deferred taxes plus valuation	0	0
Current taxes payable	<u>0</u>	<u>0</u>
Provision for Income Taxes	<u>0</u>	<u>0</u>

Below is a chart showing the federal net operating losses and the years in which they will expire.

Year	Amount	Expiration
2004	0	2024
2005	136,737	2025
2006	173,910	2026
2007	185,000	2027
2008	-	-
2009	567,232	2029
2010	980,457	2030
2011	548,990	2031
2012	1,131,326	2032
2013	1,404,786	2033
Total NOL	5,128,438	

LEASES AND OTHER COMMITMENTS:

The following is a listing of the operating leases that the Company had as of the period end and the monthly charges associated with those leases. The office lease is a renewable lease with option to renew for the next two years starting on and ending each year on, for which a new option agreement to be signed 90 days in advance of expiration date, with a 5% increase or decrease based upon the fair market value determined by the increase or decrease in the prime rate. The office equipment is a fixed cost lease with staggered expiration dates two years from the date of agreement. The lease terms provide for a one dollar buyout option at the end of the lease for which management intends on exercising, such as making the lease a capital lease. The Capital lease is depreciated over the useful life of years

	12/31/2012	12/31/13
Office rent	3,885	2680.10
Office Equipment	0	4032.70
Total Monthly	3,885	6712.80

The monthly operating leases as of 12/31/13 projected into the future for five years shows the following commitments:

	Year 1	Year 2	Year 3	Year 4	Year 5
Office Equipment	0	0	0	0	0
Real Estate	0	0	0	0	0
Total Yearly Leases	0	0	0	0	0

It is the intention of the Company's management to have its Board of Directors structured to comply with the Sarbanes-Oxley Act of 2002. The Company intends to attempt to attract potential independent directors to its board and to ask its shareholders to elect these potential directors at its next annual meeting. However, at this time, the Company's board of directors consists of four directors, all of which are insiders. At this time no directors are considered independent under the definitions of the Sarbanes-Oxley Act of 2002. It should be noted that the Company may experience difficulties attracting independent directors because, at this time, it does not have Directors and Officers Liability Insurance in place. In addition, the Company currently does not have in place an Audit Committee of the Board of Directors and therefore this committee does not currently comply with the Sarbanes-Oxley Act of 2002. The Sarbanes-Oxley Act of 2002 requires that the Audit Committee consist of three independent directors.

Because the Board of Directors, as currently structured, does not have three independent directors, it is not feasible to structure the Audit Committee in compliance with the Sarbanes-Oxley Act of 2002. It is the intent of the Management of the Company to comply with the Sarbanes-Oxley Act of 2002 as it pertains to an Audit Committee as soon as it is practicable and independent directors can be attracted to the board. The due date set forth by the Securities and Exchange Commission for compliance was May 2004.

PART E **Issuance History**

Item XVII: List of securities offering and shares issued for services in the past two years

- I. The nature of each offering: **Private Placement under Rule 504 and or Section 4 (2)**
- II. Any jurisdictions where the offering was registered or qualified: **None**
- III. The number of shares offered: **24,656,895**
- IV. The number of shares sold: **24,656,895**
- V. The price at which the shares were offered, and the amount actually paid to the issuer: **\$152,205.00**
- VI. The trading status of the shares: **Restricted**
- VII. Whether the certificates or other documents that evidence the shares contain a legend
 - (1) Stating that the shares have not been registered under the Securities Act: **Yes**

(2) Setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act: **Yes**

PART F **Exhibits**

Item XVIII **Material Contracts**

- | | |
|--|-----|
| 1- Contract with directors, vendors or suppliers | N/A |
| 2- Contract with customers | N/A |
| 3- Contract with lassoer's | N/A |

Item XIX **Articles of incorporation and Bylaws**

A - A complete copy of the Articles of incorporation is attached to this disclosure at annexure A

B - A complete copy of the issuer's by laws is attached to this disclosure at annexure B

Item XX **Purchases of Equity Securities by the Issuer and Affiliated Purchasers**

None

Item XXI **Issuers' Continuing Disclosure Obligations**

Issuers are considered to have adequate current information publicly available to the extent such information is updated to reflect new developments after the publication of initial 15c2-11 disclosure documents. In general, an issuer should provide updates to the recent balance sheet and profit and loss and retained earnings statements information required under item xii above as well as disclose changes in any other of the above disclosure items no later than 90 days after the end of any fiscal year and 45 days after the end of any fiscal quarter.

Issuer will abide with the above guidelines.

Item XXIII **ISSUER'S CERTIFICATIONS**

The undersigned hereby states that he has read the information set forth herein above, and attests hereby that, to the best of his knowledge and belief, such information is true and correct.

Signed this 31th Day of March 2014

**President
SOHM, INC.**



By: Shailesh Shah
President and CEO

Annexure A

ARTICLES OF INCORPORATION OF SOHM, INC.

KNOW ALL MEN BY THESE PRESENTS: That the undersigned incorporator being a natural person of the age of twenty-one years or more and desiring to form a body corporate under the laws of the State of Nevada does hereby sign, verify and deliver in duplicate to the Secretary of State of the State of Nevada, these Articles of Incorporation:

ARTICLE I NAME

The name of the Corporation shall be: SOHM, Inc.

ARTICLE II PERIOD OF DURATION

The Corporation shall exist in perpetuity, from and after the date of filing these Articles of Incorporation with the Secretary of State of the State of Nevada unless dissolved according to law.

ARTICLE III PURPOSES AND POWERS

1. Purposes. Except as restricted by these Articles of Incorporation, the Corporation is organized for the purpose of transacting all lawful business for which corporations may be incorporated pursuant to the Nevada Business Corporation Act.

2. General Powers. Except as restricted by these Articles of Incorporation, the Corporation shall have and may exercise all powers and rights which a corporation may exercise legally pursuant to the Nevada Business Corporation Act.

3. Issuance of Shares. The board of directors of the Corporation may divide and issue any class of stock of the Corporation in series pursuant to a resolution properly filed with the Secretary of State of the State of Nevada.

ARTICLE IV CAPITAL STOCK

The aggregate number of shares which this Corporation shall have authority to issue is: One Billion (1,000,000,000) shares of \$.0001 par value each, which shares shall be designated "Common Stock". The Board of Directors is hereby vested with authority to fix by resolution or resolutions the designations and the powers, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation the dividend rate, conversion or exchange rights, redemption price and liquidation preference, of any series of shares of Preferred Stock, and to fix the number of shares constituting any such series, and to increase or decrease the number of shares of any such series (but not below the number of shares thereof then outstanding). In case the number of shares of any such series shall be so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution or resolutions originally fixing the number of shares of such series. All shares of any

one series shall be alike in every particular except as otherwise provided by these Articles of Incorporation or the Nevada Business Corporation Act.

No holder of any shares of the Corporation, whether now or hereafter authorized, shall have any preemptive or preferential right to acquire any shares or securities of the Corporation, including shares or securities held in the treasury of the Corporation.

ARTICLE V CUMULATIVE VOTING

Each outstanding share of Common Stock shall be entitled to one vote and each fractional share of Common Stock shall be entitled to a corresponding fractional vote on each matter submitted to a vote of shareholders. A majority of the shares of Common Stock entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. Except as otherwise provided by these Articles of Incorporation or the Nevada Business Corporation Act, if a quorum is present, the affirmative vote of a majority of the shares represented at the meeting and entitled to vote on the subject matter shall be the act of the shareholders. Cumulative voting shall not be allowed in the election of directors of this Corporation.

ARTICLE VI TRANSACTIONS WITH INTERESTED DIRECTORS OR OFFICERS

No contract or other transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any corporation, firm or association in which one or more of its directors or officers are directors or officers or are financially interested, shall be either void or voidable solely because of such relationship or interest or solely because such director or officer is present at the meeting of the board of directors or a committee thereof which authorizes, approves, or ratifies such contract or transaction or solely because their votes are counted for such purpose, if:

(a) The fact of such relationship or interest is disclosed or known to the board of directors or committee and noted in the minutes, and the board or committee authorizes, approves, or ratifies the contract or transaction in good faith by a vote or consent sufficient for the purpose without counting the votes or consents of such interested director.

(b) The fact of such relationship or interest is disclosed or known to the shareholders entitled to vote and they authorize, approve, or ratify such contract or transaction in good faith by a majority vote or written consent. The votes of the common or interested directors or officers must be counted in any such vote of stockholders; or

(c) The fact of such relationship or interest is not disclosed or known to the director or officer at the time the transaction is brought before the board of directors of the corporation for action; or

(d) The contract or transaction is fair and reasonable as to the Corporation at the time it is authorized or approved.

Common or interested directors may be counted in determining the presence of a quorum at a meeting of the board of directors or a committee thereof which authorizes, approves, or ratifies such contract or transaction, and if the votes of the common or interested directors are not counted at the

meeting, then a majority of the disinterested directors may authorize, approve or ratify the contract or transaction.

ARTICLE VII
INDEMNIFICATION

The Corporation is authorized to provide indemnification of its directors, officers, employees and agents; whether by bylaw, agreement, vote of shareholders or disinterested directors or otherwise, in excess of the indemnification expressly permitted by Section 78.751 of the Nevada Business Corporation Act for breach of duty to the Corporation and its shareholders, subject only to the applicable limits upon such indemnification as set forth in the Nevada Business Corporation Act. Any repeal or modification of this Article VII or Article XI shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of such repeal or modification.

ARTICLE VIII
ADOPTION AND AMENDMENT OF BYLAWS

The initial Bylaws of the Corporation shall be adopted by its board of directors. Subject to repeal or change by action of the shareholders, the power to alter, amend or repeal the Bylaws or adopt new Bylaws shall be vested in the board of directors. The Bylaws may contain any provisions for the regulation and management of the affairs of the Corporation not inconsistent with law or these Articles of Incorporation.

ARTICLE IX
RESIDENT AGENT

The name of the Corporation's resident agent and the street address in Reno, Nevada for such resident agent where process may be served are Incorp Services Inc., 375 N. Stephanie Street Suite 1411, Henderson, Nevada 89104.

The resident agent may be changed in the manner permitted by law.

ARTICLE X
INITIAL BOARD OF DIRECTORS

The number of directors of the Corporation shall be fixed by the Bylaws of the Corporation, and the number of directors of the Corporation may be changed from time to time by consent of the Corporation's directors. The initial board of directors of the Corporation shall consist of two (2) directors. The names and addresses of the persons who shall serve as directors until the first annual meeting of shareholders and until their successors are elected and shall qualify are:

Shailesh Shah
7889 Garden Park St
Chino, CA 91708

Swati Shah
7889 Garden Park Street
Chino, CA 91708

ARTICLE XI
LIMITATION OF LIABILITY OF
DIRECTORS AND OFFICERS TO CORPORATION AND SHAREHOLDERS

No director or officer shall be liable to the Corporation or any

shareholder for damages for breach of fiduciary duty as a director or officer, except for any matter in respect of which such director or officer (a) shall be liable under Section 78.300 of the Nevada Business Corporation Act or any amendment thereto or successor provision thereto; or (b) shall have acted or failed to act in a manner involving intentional misconduct, fraud or a knowing violation of law. Neither the amendment nor repeal of this Article, nor the adoption of any provision in the Articles of Incorporation inconsistent with this Article, shall eliminate or reduce the effect of this Article in respect of any matter occurring prior to such amendment, repeal or adoption of an inconsistent provision. This Article shall apply to the full extent now permitted by Nevada law or as may be permitted in the future by changes or enactments in Nevada law, including without limitation Section 78.300 and/or the Nevada Business Corporation Act.

ARTICLE XII
INCORPORATOR

The name and address of the incorporator are: Incorp Services Inc., 375 N. Stephanie Street Suite 1411, Henderson, Nevada 89104.

IN WITNESS WHEREOF, the above-named incorporator has signed these Articles of Incorporation this 6th day of July, 2005.

/s/ Incorp
INCORP

Annexure B
BYLAWS
OF
SOHM, INC.
(A Nevada corporation)

ARTICLE I - STOCKHOLDERS

1. Certificates Representing Stock. Every holder of stock in the corporation shall be entitled to have a certificate signed by, or in the name of, the corporation by the Chairman or Vice-Chairman of the Board of Directors, if any, or by the President or a Vice-President and by the Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary of the corporation or by agents designated by the Board of Directors, certifying the number of shares owned by him in the corporation and setting forth any additional statements that may be required by the Nevada Business Corporation Act. If any such certificate is countersigned or otherwise authenticated by a transfer agent or transfer clerk or by a registrar other than the corporation, a facsimile of the signature of any such officers or agents designated by the Board may be printed or lithographed upon such certificate in lieu of the actual signatures. In case any officer or officers who shall have signed, or whose facsimile signature or signatures shall have been used on, any such certificate or certificates shall cease to be such officer or officers of the corporation before such certificate or certificates shall have been delivered by the corporation, such certificate or certificates may nevertheless be adopted by the corporation and be issued and delivered as though the person or persons who signed such certificate or certificates, or whose facsimile signature or signatures shall have been used thereon, had not ceased to be such officer or officers of the corporation.

Whenever the corporation shall be authorized to issue more than one class of stock or more than one series of any class of stock, and whenever the corporation shall issue any shares of special stock, the certificates representing shares of any such class or series or of any such special stock shall set forth thereon the statements prescribed by the Nevada Business Corporation Act. Any restrictions on the transfer or registration of transfer of any shares of stock of any class or series shall be noted conspicuously on the certificate representing such shares.

The corporation may issue a new certificate of stock in place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed and the Board of Directors may require the owner of any lost, stolen or destroyed certificate, or his legal representative, to give the corporation a bond sufficient to indemnify the corporation against any claim that may be made against it on account of the alleged loss, theft, or destruction of any such certificate or the issuance of any new certificate.

2. Fractional Share Interests. The corporation shall not be obliged to but may execute and deliver a certificate for or including a fraction of a share. In lieu of executing and delivering a certificate for a fraction of a share, the corporation may pay to any person otherwise entitled to become a holder of a fraction of a share an amount in cash specified for such purpose as the value thereof in the resolution of the Board of Directors, or other instrument pursuant to which such fractional share would otherwise be issued, or, if not specified therein, then as may be determined for such purpose by the Board of Directors of the issuing corporation; or may execute and deliver registered or bear scrip over the manual or facsimile signature of an officer of the corporation or of its agent for that purpose, exchangeable as therein provided for full share certificates, but such scrip shall not entitle the

holder to any rights as a stockholder except as therein provided. Such scrip may provide that it shall become void unless the rights of the holders are exercised within a specified period and may contain any other provisions or conditions that the corporation shall deem advisable. Whenever any such scrip shall cease to be exchangeable for full share certificates, the shares that would otherwise have been issuable as therein provided shall be deemed to be treasury shares unless the scrip shall contain other provisions for their disposition.

3. Stock Transfers. Upon compliance with provisions restricting the transfer or registration of transfer of shares of stock, if any, transfers or registration of transfers of shares of stock of the corporation shall be made only on the stock ledger of the corporation by the registered holder thereof, or by his attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the corporation or with a transfer agent or a registrar, if any, and on surrender of the certificate or certificates for such shares of stock properly endorsed and the payment of all taxes, if any, due thereon.

4. Record Date for Stockholders. For the purpose of determining the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or the allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the directors may fix, in advance, a record date, which shall not be more than sixty days nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action. If no record date is fixed, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the date on which notice is given, or, if notice is waived, at the close of business on the day next preceding the date on which the meeting is held; the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the Board of directors is necessary, shall be the day on which the first written consent is expressed; and the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at any meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

5. Meaning of Certain Terms. As used in these Bylaws in respect of the right to notice of a meeting of stockholders or a waiver thereof or to participate or vote thereat or to consent to dissent in writing in lieu of a meeting, as the case may be, the term "share" or "shares" or "share of stock" or "shares of stock" or "stockholder" or "stockholders" refers to an outstanding share or shares of stock and to a holder or holders of record of outstanding shares of stock when the corporation is authorized to issue only one class of shares of stock, and said reference is also intended to include any outstanding share or shares of stock and any holder or holders of record of outstanding shares of stock of any class upon which or upon whom the Articles of Incorporation confers such rights where there are two or more classes or series of shares of stock or upon which or upon whom the Nevada Business Corporation Act confers such rights notwithstanding that the Articles of Incorporation may provide for more than one class or series of shares of stock, one or more of which are limited or denied such rights thereunder; provided, however, that no such right shall vest in the event of an increase or a decrease in the authorized number of shares of stock of any

class or series which is otherwise denied voting rights under the provisions of the Articles of Corporation.

6. Stockholder Meetings.

Time. The annual meeting shall be held on the date and at the time fixed, from time to time, by the directors, provided, that the first annual meeting shall be held on a date within thirteen months after the organization of the corporation, and each successive annual meeting shall be held on a date within thirteen months after the date of the preceding annual meeting. A special meeting shall be held on the date and at the time fixed by the directors.

Place. Annual meetings and special meetings shall be held at such place, within or without the State of Nevada, as the directors may, from time to time, fix. Whenever the directors shall fail to fix such place, the meeting shall be held at the principal office of the corporation in the State of Nevada.

Call. Annual meetings and special meetings may be called by the directors or by any officer instructed by the directors to call the meeting.

Notice or Waiver of Notice. Notice of all meetings shall be in writing and signed by the President or a Vice-President, or the Secretary, or an Assistant Secretary, or by such other person or persons as the directors shall designate. Such notice shall state the purpose or purposes for which the meeting is called and the time when, and the place, where it is to be held. A copy of such notice shall be either delivered personally to, or shall be mailed postage prepaid, to each stockholder not less than ten nor more than sixty days before such meeting. If mailed, it shall be directed to a stockholder at his address as it appears upon the records of the corporation. Any stockholder may waive notice of any meeting by a writing signed by him, or his duly authorized attorney, either before or after the meeting; and whenever notice of any kind is required to be given under the provisions of the Nevada Business Corporation Act, a waiver thereof in writing and duly signed whether before or after the time stated therein, shall be deemed equivalent thereto.

Conduct of Meeting. Meetings of the stockholders shall be presided over by one of the following officers in the order of seniority and if present and acting - the Chairman of the Board, if any, the Vice-Chairman of the Board, if any, the President, a Vice-President, or, if none of the foregoing is in office and present and acting, by a chairman to be chosen by the stockholders. The Secretary of the corporation, or in his absence, an Assistant Secretary, shall act as secretary of every meeting, but if neither the Secretary nor an Assistant Secretary is present the Chairman of the meeting shall appoint a secretary of the meeting.

Proxy Representation. Every stockholder may authorize another person or persons to act for him by proxy appointed by an instrument in writing in all matters in which a stockholder is entitled to participate, whether by voting or participating at a meeting, or expressing consent or dissent without a meeting. Every proxy must be executed by the stockholder or by his attorney-in-fact. No proxy shall be valid after the expiration of six months from the date of its creation, unless coupled with an interest or unless the stockholder specifies in it therein the length of time for which it is to continue in force, which in no case shall exceed seven years from the date of its creation.

Inspectors. The directors, in advance of any meeting, may, but need not, appoint one or more inspectors of election to act at the meeting or any

adjournment thereof. If an inspector or inspectors are not appointed, the person presiding at the meeting may, but need not, appoint one or more inspectors. In case any person who may be appointed as an inspector fails to appear or act, the vacancy may be filled by appointment made by the directors in advance of the meeting or at the meeting by the person presiding thereat. Each inspector, if any, before entering upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the best of his ability. The inspectors, if any, shall determine the number of shares of stock outstanding and the voting power of each, the shares of stock represented at the meeting, the existence of a quorum, the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all stockholders. On request of the person presiding at the meeting, the inspector or inspectors, if any, shall make a report in writing of any challenge, question or matter determined by him or them and execute a certificate of any fact found by him or them.

Quorum. The holders of a majority of the outstanding shares of stock or of the voting power, as the case may be, shall constitute a quorum at a meeting of stockholders for the transaction of any business unless the action to be taken at the meeting shall require a different proportion. The stockholders present may adjourn the meeting despite the absence of a quorum.

Voting. Each share of stock shall entitle the holder thereof to one vote. In the election of directors, a plurality of the votes cast shall elect. Any other action shall be authorized by a majority of the votes cast except where the Nevada Business Corporation Act, the Articles of Incorporation, or these Bylaws prescribe a different percentage of votes and/or a different exercise of voting power. In the election of directors, voting need not be by ballot; and, except as otherwise may be provided by the Nevada Business Corporation Act, voting by ballot shall not be required for any other action.

7. Stockholder Action without Meetings. Except as may otherwise be provided by the Nevada Business Corporation Act, any action required or permitted to be taken by the vote of stockholders at a meeting, may be taken without a meeting if authorized by the written consent of stockholders holding at least a majority of the voting power; provided that if a different proportion of voting power is required for such action at a meeting, then that proportion of written consents shall be required. In no instance where action is authorized by written consent need a meeting of stockholders be called or notice given. The written consent must be filed with the minutes of the proceedings of the stockholders. Any written consent shall be subject to the requirements of Section 78.320 of the Nevada Business Corporation Act and of any other applicable provision of law.

ARTICLE II - DIRECTORS

1. Functions and Definition. The business and affairs of the corporation shall be managed by the Board of Directors of the corporation. The Board of Directors shall have authority to fix the compensation of the members thereof for services in any capacity. The use of the phrase "whole Board" herein refers to the total number of directors which the corporation would have if there were no vacancies.

2. Qualifications and Number. Each director must be at least 18 years of age. A director need not be a stockholder or a resident of the State of

Nevada. The number of directors constituting the Board of Directors shall be determined and may be increased or decreased, to not less than one director, by resolution of the Board of Directors.

3. Election and Term. Directors may be elected in the manner prescribed by the provisions of Sections 78.320 through 78.335 of the Nevada Business Corporation Act. The first Board of Directors shall hold office until the first election of directors by stockholders and until their successors are elected and qualified or until their earlier resignation or removal. Any director may resign at any time upon written notice to the corporation. Thereafter, directors who are elected at an election of directors by stockholders, and directors who are elected in the interim to fill vacancies and newly created directorships, shall hold office until the next election of directors by stockholders and until their successors are elected and qualified or until their earlier resignation or removal. In the interim between elections of directors by stockholders, newly created directorships and any vacancies in the Board of Directors, including any vacancies resulting from the removal of directors for cause or without cause by the stockholders and not filled by said stockholders, may be filled by the vote of a majority of the remaining directors then in office, although less than a quorum, or by the sole remaining director.

4. Meetings.

Time. Meetings shall be held at such time as the Board shall fix, except that the first meeting of a newly elected Board shall be held as soon after its election as the director may conveniently assemble.

Place. Meetings shall be held at such place within or without the State of Nevada as shall be fixed by the Board.

Call. No call shall be required for regular meetings for which the time and place have been fixed. Special meetings may be called by or at the direction of the Chairman of the Board, if any, the Vice-Chairman of the board, if any, or the President, or of a majority of the directors in office.

Notice or Actual or Constructive Waiver. No notice shall be required for regular meetings for which the time and place have been fixed. Written, oral or any other mode of notice of the time and place shall be given for special meetings in sufficient time for the convenient assembly of the directors thereat. Notice if any need not be given to a director or to any member of a committee of directors who submits a written waiver of notice signed by him before or after the time stated therein.

Quorum and Action. A majority of the whole Board shall constitute a quorum except when a vacancy or vacancies prevents such majority, whereupon a majority of the directors in office shall constitute a quorum, provided, that such majority shall constitute at least one-third of the whole Board. A majority of the directors present, whether or not a quorum is present, may adjourn a meeting to another time and place. Except as the Articles of Incorporation or these Bylaws may otherwise provide, and except as otherwise provided by the Nevada Business Corporation Act, the act of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board. The quorum and voting provisions herein stated shall not be construed as conflicting with any provisions of the Nevada Business Corporation Act and these Bylaws which govern a meeting of directors held to fill vacancies and newly created directorships in the Board or action of disinterested directors.

Members of the Board or of any committee which may be designated by the Board may participate in a meeting of the Board or of any such committee,

as the case may be, by means of a conference telephone network or a similar communications method by which all persons participating in the meeting hear each other. Participation in a meeting by said means shall constitute presence in person at any such meeting. Each person participating in a meeting by such means shall sign the minutes thereof.

Chairman of the Meeting. The Chairman of the Board, if any, and if present and acting, shall preside at all meetings. Otherwise, the Vice-Chairman of the Board, if any and if present and acting, or the President, if present and acting, or any other director chosen by the Board, shall preside.

5. Removal of Directors. Any or all of the directors may be removed for cause or without cause by the holders of at least two thirds of the voting power of the outstanding stock of the corporation. One or more of the directors may be removed for cause by the Board of Directors.

6. Committees. Whenever its number consists of two or more, the Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more of the directors of the corporation and each committee to have such powers and duties as the Board shall determine. Any such committee, to the extent provided in the resolution or resolutions of the Board, shall have and may exercise the powers and authority of the Board of Directors in the management of the business and affairs of the corporation and may authorize the seal or stamp of the corporation to be affixed to all papers on which the corporation desires to place a seal or stamp.

7. Written Action. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if, before or after the action, a written consent thereto is signed by all the members of the Board or committee, as the case may be. The written consent must be filed with the minutes of proceedings of the Board or committee.

ARTICLE III - OFFICERS

1. Officers. The corporation shall have a President, a Secretary, a Treasurer, a Resident Agent, and, if deemed necessary, expedient or desirable by the Board of Directors, a Chairman of the Board, a Vice-Chairman of the Board, a Chief Executive Officer, an Executive Vice-President, one or more other Vice-Presidents, one or more Assistant Secretaries, one or more Assistant Treasurers, and such other officers, agents and factors with such titles as the resolution choosing them shall designate. Each of any such officers, agents and factors shall be chosen by the Board of Directors or chosen in the manner determined by the Board of Directors.

2. Qualifications. Except as may otherwise be provided in the resolution choosing him, no officer other than the Chairman of the Board, if any, and the Vice-Chairman of the Board, if any, need be a director.

Any two or more offices may be held by the same person, as the directors may determine.

3. Term of Office. Unless otherwise provided in the resolution choosing him, each officer, except the Resident Agent, shall be chosen for a term which shall continue until the meeting of the Board of Directors following the next annual meeting of stockholders and until his successor shall have been chosen and qualified. The Resident Agent shall serve until his or its successor shall have been chosen and qualified.

Any officer may be removed, with or without cause, by the Board of Directors or in the manner determined by the Board.

Any vacancy in any office may be filled by the Board of Directors or in the manner determined by the Board.

4. Duties and Authority. All officers of the corporation shall have such authority and perform such duties in the management and operation of the corporation as shall be prescribed in the resolution designating and choosing such officers and prescribing their authority and duties, and shall have such additional authority and duties as are incident to their office except to the extent that such resolutions or instruments may be inconsistent therewith.

ARTICLE IV - CORPORATE OPPORTUNITY

The officers, directors and other members of management of this Corporation shall be subject to the doctrine of "corporate opportunities" only insofar as it applies to business opportunities in which this Corporation has expressed an interest as determined from time to time by this Corporation's board of directors as evidenced by resolutions appearing in the Corporation's minutes. Once such areas of interest are delineated, all such business opportunities within such areas of interest which come to the attention of the officers, directors, and other members of management of this Corporation shall be disclosed promptly to this Corporation and made available to it. The Board of Directors may reject any business opportunity presented to it and thereafter any officer, director or other member of management may avail himself of such opportunity. Until such time as this Corporation, through its board of directors, has designated an area of interest, the officers, directors and other members of management of this Corporation shall be free to engage in such areas of interest on their own and this doctrine shall not limit the rights of any officer, director or other member of management of this Corporation to continue a business existing prior to the time that such area of interest is designated by the Corporation. This provision shall not be construed to release any employee of this Corporation (other than an officer, director or member of management) from any duties which he may have to this Corporation.

ARTICLE V - PRINCIPAL AND REGISTERED OFFICES

Initially, the principal office and place of business of the corporation will be located in the State of California at 6920 Knott Avenue Suite A-C Buena Park, CA 90621 The Company's registered office in the State of Nevada is Incorp Services Inc., 375 N. Stephanie Street Suite 1411, Henderson, Nevada 89104.

Other offices and places of business may be established from time to time by resolution of the Board of Directors or as the business of the corporation may require.

The corporation shall maintain at said registered office a copy of its Articles of Incorporation, and all amendments thereto, and a copy of these Bylaws, and all amendments thereto, as certified by the Secretary of the corporation. The corporation shall also keep at said registered office a stock ledger or a duplicate stock ledger, revised annually, containing the names, alphabetically arranged, of all persons who are stockholders of the corporation, showing their places of residence, if known, and the number of shares held by them respectively or a statement setting out the name of the custodian of the stock ledger or duplicate stock ledger, and the present and

complete post office address, including street and number, if any, where such stock ledger or duplicate stock ledger is maintained.

ARTICLE VI - CORPORATE SEAL OR STAMP

The Corporate seal or stamp shall be in such form as the Board of Directors may prescribe.

ARTICLE VII - FISCAL YEAR

The fiscal year of the corporation shall be January 1 through December 31 of each year.

ARTICLE VIII - CONTROL OVER BYLAWS

The power to amend, alter and repeal these Bylaws and to make new Bylaws shall be vested in the Board of Directors subject to the Bylaws, if any, adopted by the stockholders.

I HEREBY CERTIFY that the foregoing is a full, true and correct copy of the Bylaws of SOHM, Inc., a Nevada corporation, as in effect on the date hereof.

WITNESS my hand and the seal or stamp of the corporation.

Dated this 6th day of July, 2005.

/s/ Swati Shah
President

SOHM INC.

FINANCIAL REPORT

FOR THE YAER ENDED

December 31, 2013

TABLE OF CONTENTS

	PAGE
COVER SHEET	F-1
TABLE OF CONTENTS	F-2
BALANCE SHEET, ASSETS	F-4
BALANCE SHEET, LIABILITIES AND STOCKHOLDERS' EQUITY.....	F-5
INCOME STATEMENT / STATEMENT OF OPERATIONS.....	F-6
STATEMENT OF STOCKHOLDERS' EQUITY	F-7
STATEMENT OF CASH FLOWS	F-8
NOTES TO FINANCIAL STATEMENTS	F-9-16

**SOHM INC.
FINANCIAL REPORT
FOR THE YAER ENDED
DECEMBER 31 2013**

Item 1: Exact name of the issuer and the address of its principal executive offices.

Name of the Isser: SOHM, Inc.

Principal Executive offices: 6920 Knott Avenue, Suite A-C,
Buena Park, CA 90621 USA

Telephone: (714) 522-6700
Facsimile: (714) 523-4329
Web site: www.sohm.com

Investor Relations's Officer: N/A

Investor Relations's Office: SOHM Inc.
6920 Knott Ave Suite A-C
Buena Park, CA 90621

Investor Relations's Telephone: 714-522-6700
Investor Relations's Fax: 714-523-4329
Investor Relations's Email: IR@sohm.com

Item 2 Shares outstanding.

The following table sets forth information concerning the equity securities of SOHM, Inc. as of December 31, 2013:

SECURITIES AUTHORIZED AND OUTSTANDING Class	As of	Number of Shares Authorized	Number of Shares Outstanding	Freely Tradable Shares (public float)	Total Number of Beneficial Shareholders (1)	Total Number of Shareholders of Record
Common	December 31, 2013	1,000,000,000	496,063,404	89,474,492	1760	1760
Preferred	December 31,2013	100	51	None	1	1

SOHM, INC.
YEARLY REPORT
FOR THE YEAR ENDED DECEMBER 31, 2013
BALANCE SHEET
As of DECEMBER 31, 2013 and December 31, 2012
(Unaudited)

LIABILITIES AND STOCKHOLDERS' EQUITY	As of DECEMBER 31 2013	As of December 31 2012
CURRENT LIABILITIES		
Payables	903,027	962,347
Loan Payable and other current liabilities	-	23,619
Accrued Payroll liabilities	237,660	81,168
Total Current Liabilities	1,140,687	1,067,134
LONG TERM NOTES PAYABLE	1,978,978	910,652
LOAN PAYABLE TO BANK & OTHERS	1,516,483	1,904,140
Total Liabilities	3,610,895	3,881,926
STOCKHOLDERS' EQUITY		
Common Stock, authorized 1,000,000,000 shares of stock, 496,063,404 issued and outstanding at December 31, 2013 and 432,278,806 issued and outstanding at December 31, 2012 par value \$0.001 per share and Preferred Stock authorized 100 share of stock, 51 issued and outstanding at December 31, 2012 par value \$0.001 per share	3,249,196	3,249,196
Additional Paid in Capital		-
Subscribed Shares		-
Retained Earnings (Loss)	(4,977,426)	(3,952,173)
Total Stockholders' Equity	(1,728,230)	(703,494)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	2,907,919	3,177,977

SOHM, INC.
BALANCE SHEET
as of December 31, 2013 and December 31, 2012
(Unaudited)

ASSETS

	As of December 31 2013	As of December 31 2012
CURRENT ASSETS		
Cash	10,750	182,558
Trade Receivables	573,799	505,529
Loans and Advances	223,705	444,682
Inventory	419,382	166,122
	<u>1,277,636</u>	<u>1,298,891</u>
Total Current Assets		
	<u>1,277,636</u>	<u>1,298,891</u>
PROPERTY & EQUIPMENT, net	<u>1,680,283</u>	<u>1,879,086</u>
OTHER ASSETS		
Subscribed Shares Note	-	-
Prepaid Expenses	-	-
	<u>-</u>	<u>-</u>
Total Other Assets		
	<u>-</u>	<u>-</u>
TOTAL ASSETS	<u><u>2,907,919</u></u>	<u><u>3,177,977</u></u>

SOHM, INC.
STATEMENT OF OPERATIONS / Income Statement
as of December 31, 2013 and December 31, 2012
(Unaudited)

	4 TH Quarter	Year	For the year
	October 1, 2013 to	To	Ended
	December 31, 2013	Date	December 31,
		Dec. 31, 2013	2012
INCOME			
Revenue	420,836	1,959,891	1,296,450
Total Revenue	<u>420,836</u>	<u>1,959,891</u>	<u>1,296,450</u>
COST OF SALES			
Cost of Goods Sold	94,107	1,460,261	962,577
Total Cost of Sales	<u>94,107</u>	<u>1,460,261</u>	<u>962,577</u>
Gross Profit	<u>326,728</u>	<u>499,629</u>	<u>333,873</u>
EXPENSES			
Sales and Marketing	29,443	179,003	191,137
General and Administrative	182,640	939,423	1,154,370
Research and Development	-	-	-
Depreciation Expense	48,154	200,087	119,692
Interest Expense	65,517	205,396	-
Total Expense	<u>325,755</u>	<u>1,523,910</u>	<u>1,465,199</u>
Net Income before extraordinary			
Items Extraordinary Items	<u>973</u>	<u>(1,024,281)</u>	<u>(1,131,326)</u>
Loss before Provision for	-	-	-
Income Taxes	-	-	-
Provision for Income Taxes	<u>-</u>	<u>-</u>	<u>-</u>
NET INCOME (LOSS)	<u><u>973</u></u>	<u><u>(1,024,281)</u></u>	<u><u>(1,131,326)</u></u>
Basic and Diluted Earnings			
Earnings (Loss) per Common Share	<u>-</u>	<u>-</u>	<u>-</u>
Basic and Diluted Weighted Average			
Number of Common Shares	<u>496,063,404</u>	<u>496,063,404</u>	<u>496,063,353</u>

SOHM, INC.
STATEMENT OF STOCKHOLDERS' EQUITY
as of December 31, 2012 and December 31, 2013
(Unaudited)

	Common Stock Shares	Common Stock Amount	Additional Paid in Capital	Stock Subscribed	Accumulated Deficit	Total Equity
Balance, December 31, 2004	-	-	4,200		(8,125)	(3,925)
Sales of Common Stock	260,000	260	12,740			13,000
Common Stock Issued for Conversion of LLC Interest	4,000,000	4,000	(4,200)			(200)
Common Stock Issued for Services Rendered	14,000,000	14,000	-			14,000
Deficit for year to date					(308,429)	(308,429)
Balance, December 31, 2005	18,260,000	18,260	12,740	0	(316,554)	(285,554)
Common Stock Issued for Special Interest	550,000	550	7,700			8,250
Common Stock Issued for Services Rendered	85,500,000	85,500	1,197,000			1,282,500
Common Stock Issued for Subscriber Shares Note	10,000,000			150,000		150,000
Deficit for year to date					(1,456,410)	(1,456,410)
Balance, December 31, 2006	114,310,000	104,310	1,217,440	150,000	(1,772,964)	(301,214)
Balance September 30, 2009	122,361,405	380,512	0	0	(757,645)	(377,133)
Balance December 31, 2009	237,125,016	890,972	0	0	(1,103,122)	(212,150)
Balance March 31, 2010	265,736,126	1,540,055	0	0	(1,711,599)	(171,544)
Balance June 30, 2010	271,343,626	1,575,982	0	0	(1,715,500)	(139,518)
Balance September 30 2010	283,168,626	1,750,590	0	0	(1,896,462)	(145,872)
Balance December 31 2010	329,107,088	2,059,946	0	0	(2,083,579)	(23,633)
Balance March 31 2011	333,107,088	2,059,946	0	0	(2,244,598)	(184,652)
Balance June 20, 2011	368,323,806	2,359,946	0	0	(2,522,128)	(164,182)
Balance Sept 30 2011	431,828,755	3,074,946	0	0	(2,580,349)	494,597
Balance December 31 2011	432,278,806	3,074,946	0	0	(2,632,569)	442,377
Balance December 31 2012	496,063,353	3,249,196	0	0	(3,953,145)	(703,949)
Balance December 31 2013	496,063,404	3,249,196	0	0	(4,977,426)	(1,728,230)

SOHM, INC.
STATEMENT OF CASH FLOWS
as of December 31, 2013 and December 31, 2012
(Unaudited)

	For the Year Ended December 31, 2013	For the Year Ended December 31, 2012
	<u>2013</u>	<u>2012</u>
Cash Flows from		
Operating Activities		
Net Income (Loss)	(1,024,280)	(1,131,326)
Adjustment to Retained Earnings	-	(189,844)
Accounts Receivable	(68,270)	(94,465)
Inventory	(253,260)	(45,041)
Loans and Advances	220,977	875,050
Accounts Payable	(59,320)	719,834
Loans Payable	-	-
Accrued Payroll liabilities	156,492	17,486
Current Liabilities-others	(23,619)	(201,793)
Depreciation Expense	200,087	119,692
Amortization Expense	-	-
Stock Issued for services	-	-
Stock Issued for special interest	-	-
Stock issued for capital	-	-
Net Cash Provided by Operations	<u>(851,193)</u>	<u>69,593</u>
 Cash Flows Used in Investing Activities		
Fixed Asset Purchase (Sale)	(1,285)	(1,446,618)
Other Assets	-	-
Net Cash Used for Investing	<u>(1,285)</u>	<u>(1,446,618)</u>
 Cash Flows from Financing		
Notes Payable	680,669	1,259,145
Sales of Stock	-	174,250
Capital Contributions	-	-
Subscribed Shares Note	-	-
Special Interest	-	-
Cash Flows from Financing	<u>680,669</u>	<u>1,433,395</u>
Net Increase (Decrease) in Cash	(171,808)	56,370
 Cash, Beginning of Period	 <u>182,558</u>	 <u>126,188</u>
 Cash, End of Period	 <u><u>10,750</u></u>	 <u><u>182,558</u></u>

The accompanying notes are an integral part of these statements

Schedule of Federal Taxes Paid

Twelve Months Ended December 31, 2008

None

Twelve Months Ended December 31, 2009

None

Schedule of Interest Paid

Twelve Months Ended December 31, 2010

None

Twelve Months Ended December 31, 2011

None

Schedule of Significant Non-Cash Transactions

Twelve Months Ended December 31, 2011

None

SOHM, INC.

NOTES TO FINANCIAL STATEMENTS December 31, 2013 and December 31, 2012

NOTE 1. OVERVIEW OF OPERATIONS AND ACCOUNTING POLICIES

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

The Company's operations to date have included assembling its management, marketing and sales personnel, forming strategic relationships with vendors, securing financing and launching the initial purchases of tax lien certificates.

The accompanying financial statements include financial data such as assets, liabilities, profit and loss etc. of Sohm India Pvt. Ltd. India (100% stocks of Sohm India Pvt. Ltd. Have been held by the Company and its Directors)

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying financial statements, the Company had negative cash flow from operations and incurred a net loss during the previous twenty-two months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to achieve sufficient cash flow from operations or secure adequate future financing and be therefore unable to continue as a going concern.

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments necessary for their fair presentation in conformity with U.S. generally accepted accounting principles. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results may differ from these estimates. The information included in this Form 211-75c should be read in conjunction with Management's Discussion and Analysis and financial statements and notes thereto included. Certain reclassifications have been made for consistent presentation.

F-9

Revenue Recognition

The Company generally recognizes revenue upon the accrual of interest earned on the tax lien certificates owned, as well as liquidating revenue from properties sold that the Company received through settlement of unredeemed tax lien certificates.

Deferred Revenue

The deferred revenue shown in the balance sheet is the interest earned but not collected.

Product Research and Development

F-10

Advertising, Sales & marketing

Advertising, sales & marketing costs are expensed as incurred. Advertising, sales & marketing expense totaled \$191,137 for the year-ended December 31, 2012 and for the year ended December 31, 2013 totaled \$179,003.

The company implemented new distribution of product policy, where in super distributor have been replaced by CSA & CFA for effective and regulated sales.

Inventory

Inventory is stated at the lower of cost or net realizable value. The method used for inventory is first-in first out. Inventory consists of Pharmaceutical products

Property, Equipment and Patents

Equipment is depreciated using the federal tax method over the estimated useful lives, which range from two to seven years.

Fixed assets consist of the following:

	12/31/2012	12/31/13
Fixed Assets	<u>2,034,329</u>	<u>1,913,893</u>
Total fixed assets	2,034,329	1,913,893
Less: Accumulated depreciation and Amortization	<u>(155,234)</u>	<u>(233,610)</u>
Net	1,879,086	1,680,283

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

F-11

Earnings per Share

The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic

weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

The Company has no potentially dilutive securities outstanding at the end of the statement periods. Therefore, the basic and diluted earnings (loss) per share are presented on the face of the statement of operations as the same number.

Stock Based Compensation

The Company accounts for its stock based compensation based upon provisions in SFAS No. 123, Accounting for Stock-Based Compensation. In this statement stock based compensation is divided into two general categories, based upon who the stock receiver is, namely, employees/directors and non-employees/directors. The employees/directors category is further divided based upon the particular stock issuance plan, namely compensatory and non-compensatory. Each of these divisions treats the stock issuance for accounting purposes in a specific manner. The employee/directors non-compensatory securities are recorded when the stock is sold at the sales price. The compensatory stock may be recorded in one of two different methods. Compensation is calculated and recorded either at the securities' fair value or intrinsic value. The Company has selected to utilize the fair value method for valuing and recording options.

Note 2. NOTES PAYABLE AND CAPITAL LEASE OBLIGATIONS:

Notes payable and capital lease obligations consist of the following:

There are long term notes payable and the long –term portion.

	For Year Ended	
	12/31/2012	12/31/13
Total Long Term Notes	910,652	1,978,978
Total Loan Payable to Bank & Others	1,904,142	1,516,483

F-12

Note 3. STOCKHOLDERS' EQUITY

Authorized Capital Stock

The Company has total authorized capital of 1,000,000,000 shares consisting of 1,000,000,000 shares of common stock, \$.001 par value per share and 100 preferred stock as of the date of the financial statements. Of the 1,000,000,000 shares authorized 432,278,806 shares were issued and outstanding as of December 31, 2012 and 496,063,404 shares were issued and outstanding on December 31, 2013 and of the 100 Preferred Shares authorized 51 shares were issued and outstanding as on December 31, 2013.

Stock Based Compensation Paid for Services of Non Employees

SFAS 123 provides that stock compensation paid to non employees be recorded with a value which is based upon the fair value of the services rendered or the stock given, whichever is more reliable. The common stock paid to non-employees was valued at the value of the stock issued.

Below is a schedule which shows the common stock issued and the value of the services rendered for each of the period.

Year Ended	Shares Issued	Value
December 31, 2013	0	\$0
December 31, 2012	0	\$0
December 31, 2011	0	\$0
December 31, 2010	0	\$0
December 31, 2009	0	\$0

Note 4. INCOME TAXES:

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes*. SFAS No. 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

SFAS No. 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company's opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is \$450,300 which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carryforwards, (15%). The total valuation allowance is a comparable \$ 450,300.

The total deferred tax asset is \$450,300 which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carry forwards, (15%). The total valuation allowance is a comparable \$450,300.

The provision for income taxes is comprised of the net change in deferred taxes less the valuation account plus the current taxes payable as shown in the chart below.

	09/30/2013	12/31/12
Net change in deferred taxes plus valuation	0	0
Current taxes payable	<u>0</u>	<u>0</u>
Provision for Income Taxes	<u>0</u>	<u>0</u>

F-13

Below is a chart showing the federal net operating losses and the years in which they will expire.

Year	Amount	Expiration
2004	0	2024
2005	136,737	2025
2006	173,910	2026

2007	185,000	2027
2008	-	-
2009	567,232	2029
2010	980,457	2030
2011	548,990	2031
2012	1,131,326	2032
2013	1,404,786	2033
Total NOL	5,128,438	

Note 5. LEASES AND OTHER COMMITMENTS:

The following is a listing of the operating leases that the Company had as of the period end and the monthly charges associated with those leases. The office lease is a renewable lease with option to renew for the next two years starting on and ending each year on, for which a new option agreement to be signed 90 days in advance of expiration date, with a 5% increase or decrease based upon the fair market value determined by the increase or decrease in the prime rate. The office equipment is a fixed cost lease with staggered expiration dates two years from the date of agreement. The lease terms provide for a one dollar buyout option at the end of the lease for which management intends on exercising, such as making the lease a capital lease. The Capital lease is depreciated over the useful life of years

	12/31/2012	12/31/13
Office rent	3,885	2680.10
Office Equipment	0	4,032.70
Total Monthly	3,885	6,712.80

The monthly operating leases as of 12/31/123 projected into the future for five years shows the following commitments:

	Year 1	Year 2	Year 3	Year 4	Year 5
Office Equipment	0	0	0	0	0
Real Estate	0	0	0	0	0
Total Yearly Leases	0	0	0	0	0

Note 6: GOING CONCERN

Listed below are some of the challenges which the Company is facing, and why these raise a question as to the Company's ability to continue as a going concern. Afterward, the explanation of the going concern problems, management's plans to turn the Company around are described.

Company's Challenges

The Company has survived only by raising funds. The Company must continue to raise funds in the near future to survive. Management has been successful in the past in raising these funds. There is no assurance that management can continue to find investors to cover the losses generated.

The need to provide working capital adequacy, is major challenge. For sustainable expansions of manufacturing competencies, increased stringency of regulatory framework and need for expanded management bandwidth to capture opportunities through innovation. The capacities and soft skill reinforce each other in face of outstanding opportunities. One of the major hurdle that is faced today is when large scale chain of store evaluates the products and innovation, it demand scale of response. The capacity build up requires sustained adequacy on funds as well as focus and visions of business enterprise.

F-14

Note 7. THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS

Below is a listing of the most recent accounting standards SFAS 142-144 and their effect on the Company.

SFAS 146 Accounting for Costs Associated with Exit or Disposal Activities

This statement requires companies to recognize costs associated with exit or disposal activities, other than SFAS 143 costs, when they are incurred rather than at the date of a commitment to an exit or disposal plan. Examples of these costs are lease termination costs, employee severance costs associated with restructuring, discontinued operation, plant closing, or other exit or disposal activity. This statement is effective after December 15, 2002.

SFAS 147 Acquisitions of Certain Financial Institutions – an amendment of FASB Statement No. 72 and 144 and FASB Interpretation No. 9

This statement makes the acquisition of financial institutions come under the statements 141 and 142 instead of statement 72, 144 and FASB Interpretation No. 9. This statement is applicable for acquisition on or after October 1, 2002.

F-15

SFAS 148 Accounting for Stock-Based Compensation

This Statement amends FASB Statement No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results.

The adoption of these new Statements is not expected to have a material effect on the Company's financial position, results or operations, or cash flows.

Note 8. SEGMENT INFORMATION

Segment information is presented in accordance with SFAS 131, Disclosures about Segments of an Enterprise and Related Information. This standard is based on a management approach, which requires segmentation based upon the Company's internal organization and disclosure of revenue based upon internal accounting methods. Currently management divides revenue into

two categories, earnings relative to tax lien certificates and real estate owned. To date, tax lien certificate earnings were \$2,316 and real estate owned earnings were \$0.

Note 9.COMPLIANCE WITH SARBANES-OXLEY ACT OF 2002

It is the intention of the Company's management to have its Board of Directors structured to comply with the Sarbanes-Oxley Act of 2002. The Company intends to attempt to attract potential independent directors to its board and to ask its shareholders to elect these potential directors at its next annual meeting. However, at this time, the Company's board of directors consists of four directors, all of which are insiders. At this time no directors are considered independent under the definitions of the Sarbanes-Oxley Act of 2002.

It should be noted that the Company may experience difficulties attracting independent directors because, at this time, it does not have Directors and Officers Liability Insurance in place.

In addition, the Company currently does not have in place an Audit Committee of the Board of Directors and therefore this committee does not currently comply with the Sarbanes-Oxley Act of 2002. The Sarbanes-Oxley Act of 2002 requires that the Audit Committee consist of three independent directors. Because the Board of Directors, as currently structured, does not have three independent directors, it is not feasible to structure the Audit Committee in compliance with the Sarbanes-Oxley Act of 2002. It is the intent of the Management of the Company to comply with the Sarbanes-Oxley Act of 2002 as it pertains to an Audit Committee as soon as it is practicable and independent directors can be attracted to the board. The due date set forth by the Securities and Exchange Commission for compliance was May 2004.


F-16

Item 4 Management's discussion and analysis or plan of operation.

Mission and Organizational Structure:

Sohm, Inc. (SHMN) is a generic drug manufacturer that produces and markets generic drugs for all major treatment categories globally. The core idea is to provide generics drugs cost effectively in order to bridge the gap between demand and supply . The Company not only works on applied innovation for branded generics but also provides support to white label manufacturing to build reach to ailing millions. The Company focuses on developing generic versions of brand-name products for which the patents are near expiration or expired. The Company competes on the basis of its low cost structure, aggressive growth, marketing strategy and focusing on underserved markets.

Organization Structure



Performance goals, Objectives and Results:

Non-Infringement and Early Introduction

Sohm actively reviews pharmaceutical patents and seeks opportunities to introduce its generic products where the patents have expired or are invalid. The Company intends to pursue its aggressive growth strategy through strategic alliances. These partnerships will help the Company acquire rights to pharmaceuticals, resolve patent barriers to entry while sharing development costs. The business strategy puts emphasis on non-infringement of established brand name pharmaceuticals coupled with speed of filing. The enlarged capacities through mergers, acquisitions and collaborations also bring about enlarged competencies and soft skills beyond machines and systems,

Low Cost Manufacturing Facility

The Company's manufacturing facility is located in Ahmedabad, India. The total available area is approximately 15,000 sq ft. and the current facility occupies approximately 10,500 sq ft. There is additional space available for future growth. The manufacturing facility is compliant with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and World Health Organization (WHO) regulations. The manufacturing facility is fully equipped and provides complete technical support for production activities. The location provides the Company with a low cost advantage, including lower development costs, low fixed asset costs, low clinical trial costs and low cost

of workers. The location also is surrounded by ecology of institutes from where steady supply of capable and trained professionals are easily available building competencies beyond machines and systems.

Focus on Underserved Markets

The Company intends to identify un-served or underserved niche markets to introduce its products. SHMN markets its products both directly and through partner alliance agreements. SHMN focuses on fast growing, underserved emerging markets in the Far East, South East Asia Africa, newly added European Union states, CIS Countries, and Latin America. These regions lack basic pharmaceuticals and branded drugs are either very expensive or unavailable largely. The Company recently expanded its generic drug distribution to address emerging pharmaceutical markets in Indonesia, Thailand, the Philippines and Malaysia. The Company expects to expand its range of generic pharmaceuticals through intensive research and development as well applied innovations in both generics, cosmeceuticals, and Nutraceuticals. The generic drug development strategy of the Company is represented below.

Financial Statements for the year 2011 as well as 2012 are explained in this report.

Going Concerns

The current economic environment may pose a challenge for the Company in raising funds for business. The economic recovery in the developed world remains sluggish with doubts about sustainability of recovery. The Company must continually have access to the capital markets to raise funds for operations. Lack of working capital adequacy financing may hinder further growth and slow the implementation of the business plan. The increased stringency of regulatory controls, demand for increased technological advances and expansions of capacities can be vital for sustainable growth and timely availability of high value funds can accelerate the process. Building soft skill and management bandwidth is also linked with capacity reinforcements and working capital adequacies to attract, retain and deploy highly knowledge-based skill force.

The generic drugs market has significant upward growth potential. This has encouraged large and small players to tap into this opportunity. Increased competition may impact growth and margins negatively.

Pharmaceutical companies are using state and federal legislative and regulatory means to delay generic competition. If pharmaceutical companies succeed in limiting the use of generics, it would diminish SHMN's business prospects. We believe generic drugs will gain popularity as they are cost effective with the same physiological effectiveness.

Item 5 Legal proceedings.

NONE

Item 6 Defaults upon senior securities.

NONE

Item 7 Other information.

NONE

Item 8 Exhibits.

A - A complete copy of the Articles of incorporation is attached to this disclosure at annexure A

B - A complete copy of the issuer's by laws is attached to this disclosure at annexure B

Item 9 Certifications.

I, Shailesh Shah, certify that:

1. I have reviewed this annual disclosure statement of Sohm, Inc., (SHMN);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Signed this 31th Day of March, 2013

President

SOHM, INC.



By: Shailesh Shah
President and CEO